CompletedNot Applicable

GCWB1176 Evaluates the Effectiveness and Safety of Immune Function

South Korea100 participantsStarted 2023-01-17

Plain-language summary

This human application test was planned to evaluate the effectiveness and safety of immunodefinition compared to the placebo when the GCWB1176 was consumed for those whose white blood cell level was normal or somewhat decreased.

Who can participate

Age range19 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At the time of screening, 19 or 75 years
✓. A person with a peripheral blood leukocyte level measured in Visit 1, 3x10\^3 cells/μl or more, 8x10\^3 cells/μl
✓. Those who are more than one of the following standards
✓. Those with a stress awareness scale (PSS) 16 or more
✓. A person who agrees to participate in this human application test before the start of the human test and writes a written consent form

Exclusion criteria

✕. Those who are currently treating drugs due to underlying disease, etc.
✕. Hypertension patients (systolic blood pressure 140 mmHg or higher or dichotomous blood pressure 90 mmHg or higher, human application test target 10 minutes stabilized)
✕. Patients with diabetes with an fasting blood sugar at least 126 mg/dL or administering urine disease (oral blood sugar, insulin, etc.)
✕. Those who are 0.1 UIU/mL or less, or 10 UIU/mL or more
✕. Those who have vaccinated vaccines (influenza, corona, shingles that can affect immunity) within 3 months of visiting 1
✕. A disease that can affect immune responses such as adult -like and rhinitis
✕. AST (GOT) or ALT (GPT) is three times more than the normal upper limit of the embodiment
✕. Those who are 1.5 times more than the normal upper limit of Creatinine

What they're measuring

Change amoust of NK Cell Activity

Timeframe: week 0, 4 and 8

Trial details

NCT IDNCT05632341

SponsorGreen Cross Wellbeing

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-01-31

View on ClinicalTrials.gov More Immune Function trials